Burt Adelman, M.D.
Burt Adelman, M.D., has served as a member of our board of directors since April 2016. Dr. Adelman was Executive Vice President, Research and Development and Chief Medical Officer of Dyax Corp., or Dyax, a biotechnology company, from February 2012 until its acquisition by Shire Plc in January 2016. Prior to joining Dyax, he worked at Eleven Biotherapeutics, Inc., a biotechnology company, where he served as interim President of Research and Development from 2009 to 2010 and as Senior Advisor from February 2011 until December 2011. As Senior Advisor, Dr. Adelman consulted with Eleven Management to ensure a successful leadership transition. From 1991 to 2007, Dr. Adelman held positions of increasing responsibility at Biogen Inc. (formerly Biogen Idec Inc.), a global biotechnology company, ultimately as Executive Vice President, Portfolio Strategy. Since 1998, Dr. Adelman has served as a lecturer in medicine at Harvard Medical School and as an Associate Physician at Brigham and Women’s Hospital. Dr. Adelman holds an M.D. from Cornell Medical College and a B.S. in biology from Trinity College. He completed residency training and a hematology fellowship at the Peter Bent Brigham Hospital.